Clinical Trial Update: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial from China tests a bortezomib-lenalidomide-dexamethasone regimen followed by BCMA CAR-T therapy in transplant-ineligible patients wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasma Cell Leukemia

Drugs mentioned

• BCMA CAR-T therapy (BCMA-targeted chimeric antigen receptor T-cell therapy)
• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Plasma Cell Leukemia | Phase 2 | Status: RECRUITING